

MarketVue®

Cold Agglutinin Disease

July 2022



MarketVue®: Cold Agglutinin Disease

UNDERSTAND THE COLD AGGLUTININ DISEASE MARKET

MarketVue market landscape reports combine primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.

Every **MarketVue** includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.

Methodology: Research is supported by 9 qualitative interviews with key opinion leaders, a quantitative survey with 25 U.S. physicians and secondary research. Qualitative interview participants include Hematologists and Hematologist/Oncologists in the U.S. (n=4) and EU (n=5).

Geographies covered: United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)

TOPICS COVERED

EPIDEMIOLOGY: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments

CURRENT TREATMENT: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment

UNMET NEEDS: Identify opportunities to address treatment or disease management gaps

PIPELINE ANALYSIS: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs

VALUE AND ACCESS: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing

Why MarketVue?

- **PMR-Driven** – Insights informed by qualitative interviews and/or quantitative surveys
- **Senior Team** – Experienced team members (10+ years in pharma market research) lead the research
- **Strategic** – Delivered in a concise and strategic report template vetted by pharmaceutical industry professionals
- **Fresh** – New reports or report refreshes delivered in as little as 15 business days



MarketVue®: Cold Agglutinin Disease

UNDERSTAND THE COLD AGGLUTININ DISEASE MARKET

COMPANIES MENTIONED

- Sanofi / Genzyme
- Swedish Orphan Biovitrum AB (SOBI)
- Apellis Pharmaceuticals
- Novartis

DRUGS MENTIONED

- Rituximab (Rituxan)
- Bendamustine
- Fludarabine (Fludara)
- Sutimlimab (Enjaymo)
- Corticosteroids
- Venetoclax (Venclexta)
- Bortezomib (Velcade)
- Ibrutinib (Imbruvica)
- Iptacopan (Fabhalta)
- Pegcetacoplan (Empaveli)
- SAR445088

MarketVue®: Cold Agglutinin Disease

Table of Contents

1. DISEASE OVERVIEW	5 - 6
A rare, cold-activated, autoimmune bone marrow disorder characterized by hemolytic anemia	5
Figure 1.1. Classical complement pathway in CAD	5
CAD is characterized by anemia-related and cold-associated symptoms	6
Table 1.1. Clinical presentation of CAD	6
Figure 1.2. Hematologist-reported segmentation of their CAD patient population	6
2. EPIDEMIOLOGY & PATIENT POPULATIONS	7
Disease definition	7
Figure 2.1 – Diagnosed prevalent cases of CAD by region	7
Table 2.1 – Diagnosed prevalent and drug-treated patients in the U.S. and EU5	7
3. DIAGNOSIS AND CURRENT TREATMENT	8 - 19
Diagnosis Overview	8
Figure 3.1. Diagnostic pathway for CAD patients	8
B-cell and complement-directed therapy are the current standards of care	9
Overview	9
Figure 3.2. Treatment goals for CAD	9
Figure 3.3. Current Treatment Patient Share	9
Treatment flow for CAD	10
Figure 3.4. Treatment algorithm for CAD	10
Rituximab-based regimens are the most widely used treatments for CAD in US and EU	11
Figure 3.5. Hematologist rating (n=25) of current therapy effectiveness in CAD	11
Figure 3.6. Hematologist-reported percentage of CAD patients who are refractory to rituximab	11
There is room for improvement over existing treatments	12
Hematologists' opinions on current treatments	13
Severity of anemia and dosing are critical drivers of treatment choice between rituximab and sutimlimab	14
Sutimlimab is the first and only USFDA-approved drug for primary CAD	15
Sutimlimab is viewed favorably in the US and EU, with a few reservations	16
Figure 3.7. Enjaymo's advantages observed in clinical practice	16
Figure 3.8. Percentage of hematologists who rated Sutimlimab as "extremely favorable" for its attributes	16
Figure 3.9. Percentage of hematologists familiar with sutimlimab (Enjaymo)	16

MarketVue®: Cold Agglutinin Disease

Table of Contents

Hematologists' perception of Sutimlimab	17
Key treatment dynamics that shape disease management and drug use in CAD	18
Table 3.1 Must-know CAD treatment dynamics	18
Figure 3.10. Hematologist-reported percentage of patients with unsatisfactory outcomes with current CAD treatments	18
Complement pathway inhibition is the future of CAD therapy	19
Figure 3.11. Important dynamics of CAD market evolution	19
4. UNMET NEED	20 - 22
Overview	20
Figure 4.1 – Top unmet needs in CAD	20
Figure 4.2 – Physician-reported unmet needs in CAD	20
Important unmet needs in treating CAD remain	21
Figure 4.3 – Three unmet needs in CAD despite the addition of sutimlimab as a treatment option	21
Non-clinical barriers to care - physician perspective	22
Figure 4.4 – Percent of hematologists who see this as a barrier to receiving drug therapy	22
5. PIPELINE ANALYSIS	23 - 25
Overview	23
Figure 5.1. Number of emerging CAD therapies whose clinical trial primary end points target top unmet needs	23
Pipeline for CAD is limited	24
Table 5.1. Comparison of ongoing trials of complement-mediated therapies in CAD	24
Emerging therapies are complement inhibitors	25
Figure 5.2. Percentage of hematologists who rated the following emerging therapies as “promising”	25
Figure 5.3. Percentage of hematologists who rated emerging target or approach as “promising”	25
6. VALUE & ACCESS	26 - 31
Overview	26
Table 6.1 – Current therapy pricing	26
Table 6.2 – Typical commercial payer coverage of Rituxan and Enjaymo (e.g., United Healthcare, Aetna, BlueCross BlueShield, Cigna)	26
Key market access dynamics that will continue to shape treatment use	27
Figure 6.1 – CAD patients by insurance type	27

MarketVue®: Cold Agglutinin Disease

Table of Contents

Thoughts from European physicians surrounding current and future access to CAD therapies	28
Drug Analogue: Soliris, Ultomiris, and Empaveli in PNH	29
Overview	29
Commercial payer requirement of drug analogues	29
Table 6.3. Summary of commercial insurance requirements for Empaveli, Ultomiris, and Soliris	29
Drug Analogue: Soliris in PNH	30
Overview	30
Figure 6.2. Annual cost (WAC) of Soliris (000s), 2007 – 2021	30
Figure 6.3. Key market access pillars for Soliris in PNH	30
Drug Analogue: Empaveli and Ultomiris in PNH	31
Overview	31
Figure 6.4. Strategies used by Ultomiris and Empaveli to compete with Soliris	31
Thoughts from European physicians surrounding current and future access to CAD therapies	31
7. METHODOLOGY	32 – 33
Primary market research approach	32
Epidemiology methodology	33

Meet the REACH Team



DANIELLE DRAYTON, PhD., Dr. Drayton is CEO and Founder of REACH Market Research. She is a seasoned business leader and pharmaceutical market researcher. Prior to founding REACH, Dr. Drayton led the Biopharma Market Assessment business at Decision Resources Group (DRG) comprised of market research, RWD analytics, and consulting business lines. In her 14 years at DRG, she worked with 48 of the top 50 pharmaceutical companies and countless biotech companies that involved exhaustive evaluation of unmet need, target product profiles, commercial potential and new product adoption, and company competitiveness. She also has extensive experience conducting product and market opportunity assessments, portfolio analysis, product and therapeutic area strategy, product valuation and sales forecasting, and pre-launch planning. Dr. Drayton completed a postdoctoral fellowship at the Harvard Medical School, received a Ph.D. in Immunobiology from Yale University, and earned a B.S. in Microbiology and Immunology from the University of Miami (Florida).



MELISSA CURRAN is the Director of Product Management at REACH. Melissa has over 10 years of life sciences market research and consulting experience spanning from bespoke strategy consulting to syndicated market research product development and management. Prior to joining REACH, she worked at Decision Resources Group (DRG) for 7 years assisting pharmaceutical and biotechnology commercial teams across the product lifecycle to inform strategic decision making. Melissa is particularly passionate about new product planning and portfolio management, especially in the rare disease space where data can be scarce, and decision-making can be challenging. Specific types of strategic assessments Melissa specializes in include market landscape assessments, commercial opportunity assessment, patient journey mapping, product positioning and TPP optimization, portfolio prioritization, and competitive intelligence. She also has extensive experience working across various market research methodologies including qualitative interviews, quantitative surveys, patient chart audits, real world claims and EHR data, conjoint analysis and secondary research. Melissa received her bachelor's degree in Biology and minor in Business from Providence College.



MICHAEL HUGHES, MSc, Ph.D., Dr. Hughes is the Director of Research at REACH. He has worked in academia, regulatory affairs (NICE) and in RWE and epidemiology consultancies, leading the global epidemiology team at Clarivate (previously Decision Resources Group) for many years. Over that period, he has built numerous new approaches to epidemiological forecasting and imputation, which now form industry best-practice. He has built syndicated and custom epidemiological models and forecasts for many blockbuster drugs across many therapeutic areas, often using a hybrid approach sourcing data from multiple types of dataset and primary market research. He has recently worked on projects in prostate cancer, amyloidosis, anaphylaxis and multi-drug resistant UTIs, among others. He has supported the needs of both big pharma, including Novartis, GSK and Johnson and Johnson, as well as smaller companies and biotechs.

Meet the REACH Team



TYLER JAKAB, MPH is an analyst at REACH Market Research. He is responsible for conducting both primary and secondary market research regarding rare disease therapies to be integrated into market research reports for life science clients. Tyler is a recent graduate of Boston University School of Public Health where he obtained an MPH in Epidemiology of Biostatistics. Prior to joining REACH, he held roles in which he was responsible for health policy analysis, tobacco control research, and health communication. He has extensive experience in data analysis, as well as manuscript and report writing. Tyler also earned a BS in Psychology and Anthropology from the University of North Carolina at Chapel Hill.



BAYLEY KOOPMAN is a Research Associate at REACH Market Research. At REACH, Bayley supports both primary and secondary market research through literature reviews and working with qualitative data. He recently graduated from Tufts University with a B.S. in Biology where he studied the interdisciplinary OneHealth approach for public health and the environment. During this time, Bayley founded an early-stage consumer product startup, which became a finalist team in two consecutive Tufts University Entrepreneurship Pitch Competitions. Prior to joining REACH, Bayley also held roles in regulatory affairs in the rare-disease pharmaceutical industry and veterinary practice.



BRIANA MULLINS is a current PhD student At NYU School of Medicine studying the immunological progression of disease in psoriatic arthritis. She currently does both laboratory research and computational biology. Previously she earned her undergraduate degree in Biochemistry at New York University (NYU) and worked in the Blaser Lab studying the human microbiome. She also received an MSc. in Population Health at the University College London (UCL) and conducted antibiotic prescription research using the UK THIN Database. Before starting her PhD Briana worked at Decision Resources Group as an Associate Epidemiologist.